Reminder What Not To Say To Breast Cancer People

As part of the universal pinkification of October, Good Housekeeping magazine has a section on breast cancer (who knew?). But one thing they do include is a list of 15 things not to say to breast cancer people.You ’re going to be fineEverything happens for a reasonYou don ’t look sick – you look greatMy brother ’s friend had breast cancer here’s what happened to her.That ’s why I don’t use antiperspirant (deodorant, underwire bras)I hate my large breasts; I ’d love to get rid of them.How did they find it? What stage was it?Have you tried cutting out sugar?Can I do anything for youYou ’re a badass! You’ll kick cancer!We could all be hit by a bus tomorrowStay positiveAt least you have your hairI ’m praying for you, miracles do happen!At least you ’re single, and you don’t have kids to worry about.Most of these I find to be just plain rude. If someone has cancer, any type, they are so stressed they do not care about most of these. Even asking them if you can do something for them can be stressful. They have to stop and think if they need anything, which they probably do, but can't think of, so you added more stress, and they just say'nothing, thank you.'If you need more understanding here, go read the rest of the article atGood Housekeeping.Just think before you say anything (and insert your foot in your mouth). The best thing you can say to any one with cancer is'how are you feeling today?'A simple ea...
Source: Caroline's Breast Cancer Blog - Category: Cancer & Oncology Tags: being a patient Halloween pinkification Source Type: blogs

Related Links:

Is the combination of oral metronomic vinorelbine plus letrozole safe and effective for ER+ breast cancer?Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
      ·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, wh...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
AbstractPurposeTo determine whether a red clover preparation plus dietary intervention administered to premenopausal women with breast cancer (BC), improves menopausal symptoms due to anti-oestrogen treatment, and hence promotes compliance with tamoxifen, prevents weight gain and is safe.MethodsSurgically-treated premenopausal women with oestrogen receptor (ER) positive disease taking tamoxifen were recruited to a prospective double-blind randomized trial (NCT03844685). The red clover group (N = 42) received one oral tablet/day (Promensil® Forte) containing 80  mg red clover extract for 24 month...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractAnastrozole is an aromatase inhibitor. Anastrozole competitively inhibits the aromatase enzyme, which synthesizes estrogen. It is used for estrogen receptor-positive breast cancers. A woman with breast cancer and anastrozole-induced dermatitis is described; the cutaneous side effects associated with aromatase inhibitors are also reviewed. Skin-related adverse events associated with aromatase inhibitor use are uncommon and may be delayed in appearance; the time of onset ranges from less than 5  days to 6 months (median 2 months). They present as either vasculitis, erythema nodosum, subacute cutaneous ...
Source: Dermatology and Therapy - Category: Dermatology Source Type: research
Pemphigus is a chronic autoimmune blistering disorder, characterized by (muco-)cutaneous erosions due to autoantibodies against desmoglein 3 and/or 1. Pemphigus induction might be associated with drugs, malignancy or radiation therapy (RT); the latter being only rarely described. A rigorous literature review revealed around 30 cases of RT-associated pemphigus, which had been primarily treated with topical and/or systemic steroids, in some cases also dapsone or few other immunosuppressive agents were given. The most common underlying cancer type was breast cancer. We here present a 63-year-old male patient, who was pre-trea...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, we assessed the impact of interacting medication and pharmacogenetic variation to better explain apixaban concentration differences among 358 Caucasian AF patients. Genotyping (ABCG2,ABCB1,CYP3A4*22,CYP3A5*3) was performed by TaqMan assays, and apixaban quantified by mass spectrometry. The typical patient was on average 77.2  years old, 85.5 kg, and had a serum creatinine of 103.1 µmol/L. Concomitant amiodarone, an antiarrhythmic agent and moderate CYP3A/ABCB1 inhibitor, the impaired-function variantABCG2 c.421C  >  A, and sex predicted higher apixaban concentrations whe...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast cancer. The primary objective was to determine the maximum tolerated dose (MTD) of RO4929097. Secondary objectives were to determine real-time pharmacokinetics of RO4929097 and paclitaxel, safety and pathologic (pCR) complete response to study treatment. Eligible patients, initiated carboplatin at AUC 6 administered intravenously (IV) on day 1, weekly paclitaxel at 80  mg/m2 IV and RO4929097 10 mg dai...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
This study provides useful concepts in assessing the contribution of BCRP on intestinal absorption in drug discovery and development process.
Source: Pharmacology Research and Perspectives - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
In metastatic breast cancer, top news at SABCS 2019 focused on two highly active drugs in HER2+ disease, an oral paclitaxel in TNBC, and evidence for a new standard front-line therapy in HR+ disease.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news
Abstract Dysregulation of calcium homeostasis is a major mechanism of doxorubicin (DOX)-induced cardiotoxicity. Treatment with DOX causes activation of sarcoplasmic reticulum (SR) ryanodine receptor (RYR) and rapid release of Ca2+ in the cytoplasm resulting in depression of myocardial function. The aim of this study was to examine the effect of dantrolene (DNT) a RYR blocker on both the cardiotoxicity and antitumor activity of DOX in a rat model of breast cancer. Female F344 rats with implanted MAT B III breast cancer cells were randomized to receive intraperitoneal DOX twice per week (12 mg/kg total dose), 5...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
More News: Blogging | Breast Cancer | Cancer | Cancer & Oncology | Children | Legislation | Milk | Oral Cancer | Sugar